BMS-779788-EXEL04286652-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEBMS-779788Cat. No.: HY-19919CAS No.: 918348-67-1Synonyms: EXEL04286652; XL-652; BMS-788分式: CHClNOS分量: 509.06作靶點(diǎn): LXR作通路: Metabolic Enzyme/Protease儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DM

2、SO : 31 mg/mL (60.90 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.9644 mL 9.8220 mL 19.6440 mL5 mM 0.3929 mL 1.9644 mL 3.9288 mL10 mM 0.1964 mL 0.9822 mL 1.9644 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 BMS-779788是LXR的部分激動

3、劑，其對LXR和LXR的IC50值分別為68和 14 M。IC50 & Target IC50: 68 nM (LXR); 14 nM (LXR) 1體外研究The LXR selective partial agonist BMS-779788 is identified with potent induction of ATP binding transporters1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEABCA1 and ABCG1 in human whole blood (EC50=1.2 M, 55% efficacy)

4、2.體內(nèi)研究 BMS-779788 induces LXR target genes in blood in vivo with an EC50=610 nM, a value similar to its in vitroblood gene induction potency. BMS-779788 is 29- and 12-fold less potent than the full agonist T0901317 inelevating plasma triglyceride and LDL cholesterol, respectively, with similar resul

5、ts for plasma cholesterylester transfer protein and apolipoprotein B 1. In mice BMS-779788 displays peripheral induction of ABCA1at 3 and 10 mpk doses with no significant elevation of plasma or hepatic triglycerides at these doses,showing an improved profile compared to a full pan-agonist 2.PROTOCOL

6、Animal Monkeys: Male cynomolgus monkeys are used in the study. For a single-dose pharmacokinetic (PK)-Administration 1 pharmacodynamic (PD) study, 2 animals each are treated either with vehicle 0.5% carboxymethyl celluloseand 2% Tween 80 in purified water) or 1 mg/kg BMS-779788. For the 7 day PD stu

7、dy, 18 animals arerandomized into 6 treatment groups (N=3/group; 3-6 kg) and received the following treatments at 7 AM dailyfor 7 days by oral gavage: vehicle, 10 mg/kg per day T0901317 and 0.3, 1, 3, or 10 mg/kg per day BMS-779788 1.MCE has not independently confirmed the accuracy of these methods.

8、 They are for reference only.REFERENCES1. Kirchgessner TG, et al. Pharmacological characterization of a novel liver X receptor agonist with partial LXR activity and a favorablewindow in nonhuman primates. J Pharmacol Exp Ther. 2015 Feb;352(2):305-14.2. Kick E, et al. Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXR. Bioorg MedChem Lett. 2015 Jan 15;25(2):372-7.McePdfHeightCaution: Product has not been fully validated for medical applic